Golidocitinib
Golidocitinib 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Peripheral T Cell Lymphoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
17 项
全球在招研究
5 项
已进入 III/IV 期
4 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- M.D. Anderson Cancer Center
- Sun Yat-sen University
- Fudan University
- Beijing Friendship Hospital
- Dizal Pharmaceuticals
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Peking University Cancer Hospital & Institute
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
中国、美国、中国台湾、Thailand
正在招募患者的 Golidocitinib 研究
Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)
II 期招募中中国NCT06733051A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL
I 期 / II 期招募中中国NCT06966154Golidocitinib Combined With Selinexor for CAEBVD
II 期 / III 期招募中中国NCT07369739Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
I 期 / II 期招募中中国NCT07496229A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study
II 期招募中美国NCT06630091Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy
III 期招募中中国NCT07414758Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC
II 期招募中中国NCT07110103Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
I 期 / II 期招募中中国NCT07093710A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC
I 期招募中中国NCT06969612PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL
II 期招募中中国NCT07380984Golidocitinib Plus CHOP in Newly Diagnosed PTCL
I 期 / II 期招募中中国NCT06739265Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma
III 期招募中中国NCT07300514A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
I 期 / II 期招募中中国NCT06855823Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)
I 期 / II 期招募中中国NCT07525466Prospective Single-Arm Clinical Trial of GO Regimen for HLH.
II 期 / III 期招募中中国NCT07339345Golidocitinib and Chidamide for Cutaneous T-Cell Lymphoma
I 期 / II 期招募中中国NCT07754890A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
III 期招募中中国中国台湾ThailandNCT07234162
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。